IDSA and HIVMA recently challenged a sudden price increase for pyrimethamine, a generic drug used to treat toxoplasmosis. Turing Pharmaceuticals acquired the drug in mid-August and increased the price from $13.50 to $750 per tablet. After hearing concerns from IDSA and HIVMA members, IDSA President Stephen Calderwood, MD, FIDSA, and HIVMA Chair Adaora Adimora, MD, FIDSA, wrote to Turing officials urging the company to revise its pricing strategy. |
The jump in the drug price caught the attention of policy-makers and the media, which led to a groundswell of media requests for interviews with HIVMA spokespersons resulting in over 100 news stories quoting HIVMA and IDSA experts, including pieces in the New York Times, USA Today, The Washington Post and NBC News. Immediately following the news coverage, Turing announced that it would lower the price of the drug within a few weeks. The new price has not been disclosed.
< Previous Article | Next Article >